Drugs / ZE94-0605
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07524140 | Apr 2026 → Jan 2028 expected | metastatic malignant neoplasm | Eilean Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZE94-0605 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07524140 ↗ |
| Route | Oral | “Oral capsules QD” NCT07524140 ↗ |